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Background. Nearly 20% of human cancers worldwide have an infectious etiology with the most prominent examples being
hepatitis B and C virus-associated hepatocellular carcinoma and human papilloma virus-associated cervical cancer. There is an
urgent need to find new approaches to treatment and prevention of virus-associated cancers. Methodology/Principal
Findings. Viral antigens have not been previously considered as targets for treatment or prevention of virus-associated
cancers. We hypothesized that it was possible to treat experimental HPV16-associated cervical cancer (CC) and Hepatitis B-
associated hepatocellular carcinoma (HCC) by targeting viral antigens expressed on cancer cells with radiolabeled antibodies
to viral antigens. Treatment of experimental CC and HCC tumors with
188Re-labeled mAbs to E6 and HBx viral proteins,
respectively, resulted in significant and dose-dependent retardation of tumor growth in comparison with untreated mice or
mice treated with unlabeled antibodies. Conclusions/Significance. This strategy is fundamentally different from the prior
uses of radioimmunotherapy in oncology, which targeted tumor-associated human antigens and promises increased specificity
and minimal toxicity of treatment. It also raises an exciting possibility to prevent virus-associated cancers in chronically
infected patients by eliminating cells infected with oncogenic viruses before they transform into cancer.
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INTRODUCTION
It has been estimated that nearly 20% of human cancers worldwide
have an infectious etiology [1]. Most of these tumors are of viral
origin, and include firmly established associations of hepatitis B virus
(HBV) and hepatitis C virus (HCV) with hepatocellular carcinoma;
and of human papillomavirus (HPV)-with cancers of the cervix,
anus, vulva, vagina; as well as associations of oropharynx Epstein-
Barr virus (EBV) with lymphoma and nasopharyngeal carcinoma;
human T lymphotropic virus type 1 (HTLV-1)-with adult T-cell
leukemia/lymphoma, and human herpes virus 8 (HHV-8)-with
Kaposi sarcoma [2–7]. In combination, these virus-associated
tumors represent a burden of approximately 1.3 million cases of
cancer each year, with HBV/HCV-associated liver cancer account-
ing for 523,000 cases, and HPV-associated tumors accounting for
561,000 cases[8]. The need to find new approaches to the treatment
and prevention of virus-associated cancers is obvious and urgent.
Radioimmunotherapy (RIT) utilizes antigen-antibody binding
to deliver cytotoxic doses of particulate radiation to tumor cells
[9,10]. RIT, for example, has been used to successfully treat
refractory and recurrent lymphomas, with two radiolabeled
monoclonal antibodies (mAb) targeted against CD20 (ZevalinH
and BexxarH) having received FDA approval for this purpose. It is
likely, in fact, that RIT will become a first line treatment for
follicular lymphoma [11]. This ‘‘traditional’’ cancer RIT targets
‘‘self’’ antigens. Recently, we demonstrated that RIT has also
broad potential for the treatment of fungal and bacterial infections
through targeting of microbial antigens with radiolabeled mAbs in
experimental models of fungal and bacterial infections [12,
reviewed in 13]. In addition, we found that HIV-1 infected cells
could be eliminated in vitro and in vivo by targeting gp120 and
gp41 viral glycoproteins expressed on the surface of infected cells
with radiolabeled viral protein-specific mAbs [14].
We hypothesized that RIT targeted against viral antigens could
be used in the treatment of a broad range of viral infectious
diseases and virus-associated tumors [15,16]. Many virus-associ-
ated cancers express viral antigens either internally or on their
surfaces. It is important to note that even viral antigens expressed
intracellularly are potential targets for RIT, since tumor cell
turnover is likely to result in the release of these proteins into the
interstitial space of the tumor. This approach is fundamentally
different from the previously described uses of RIT which target
tumor-associated antigens that are ‘‘self’’ (i.e., human) proteins. By
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PLoS ONE | www.plosone.org 1 October 2007 | Issue 10 | e1114targeting viral and not ‘‘self’’ proteins, it is hoped that radiolabeled
mAbs can be more specifically concentrated within tumor tissue,
resulting in greater efficacy and less toxicity. Here we describe the
proof-of-principle experiments aimed at demonstrating the
feasibility of treating experimental HPV16-associated cervical
cancer (CC) and Hepatitis B-associated hepatocellular carcinoma
(HCC) by targeting viral antigens expressed on cancer cells with
radiolabeled antibodies to viral antigens.
RESULTS
Selection of a cell line-antigen combination to act as
an experimental cervical cancer (CC) model
To evaluate the potential of RIT to target viral antigens incancers of
viral etiology, we needed to identify tumor cell lines that expressed
the target antigen and could also be implanted into nude mice. We
selected HPV16 and HPV18 cell lines, since these two HPV types
account for approximately 70% of cervical cancers and a significant
fraction of head and neck tumors [17,18]. The E6 and E7
oncoproteins were considered the best potential antigenic targets,
since these proteins are expressed in essentially all cervical cancer
cells, whereas other viral genes may be lost. Mutational analysis has
shown that the E6 and E7 viral oncoproteins are necessary and
sufficient for the immortalization ofhumancells byHPV.Therefore,
we assessed by Western blot the expression of E6 and E7 in three
human cervical carcinoma cell lines–HPV16-positive CasKi and
SiHa cell lines and HPV18-positive HeLa S3 cell line. While CasKi
cells expressed both E6 and E7 antigens (Fig. 1a, b), SiHa and HeLa
S3 cell lines had no measurable expression of E6 antigen (results not
shown) but did express E7 protein (Fig. 1d, e); albeit, the level of E7
expression was low in SiHa cells (Fig. 1d).
The proteasome inhibitor MG132 reduces the degradation of
ubiquitin-conjugated proteins in mammalian cells without affecting
ATPase or isopeptidase activities. MG132 has been reported to
resultinincreasedlevelsofE6andE7proteinsincervicalcancercells
[19,20]. As higher amounts of target antigens can potentially
improve RIT results, we investigated the influence of pre-treatment
of CC cells with proteasome inhibitor MG132 on the levels of E6
and E7 expression. Fig. 1a and b shows that in CasKi cells pre-
treatment with MG132 caused an increase in expression of both E6
and E7, with the greatest level of expression achieved with use of 2
and 5 mg/mL of MG132 which subsided when higher doses were
used. Prolongation of the incubation period of CasKi cells with
MG132 did not result in greater E6 expression. In fact, we observed
Figure 1. Expression of E6 and E7 in human cervical carcinoma cell lines and of HBx in hepatocellular carcinoma cell line by Western blot and
effect of MG132 proteasome inhibitor treatment on the levels of E6, E7 and HBx in these cell lines: a) E6 from protein extracts of CasKi cells
treated with MG132 for 3 hrs; b) E7 from protein extracts of CasKi cells treated with MG132 for 3 hrs; c) E6 from protein extracts of CasKi cells treated
with MG132 for 6 hrs; d) E7 from protein extracts of SiHa cells treated with MG132 for 3 hrs; e) E7 from protein extracts of HeLa S3 cells treated with
MG132 for 3 hrs; f) HBX from protein extracts of Hep 3B2.1-7 cells treated with MG132 for 3 hrs.
doi:10.1371/journal.pone.0001114.g001
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MG132 (Fig. 1c), which might reflect an increase of protein
degradation after more than 3 hr of incubation. Similar experiments
were performed for E7 protein in SiHa and HeLa S3 cell lines
(Fig. 1d,e). SiHa cells did not demonstrate an appreciable increase in
the E7 levels (Fig. 2d); whereas, E7 levels did increase slightly for
HeLa S3 cells treated with 1 and 2 mg/mL MG132 (Fig. 1e). Given
reliable and high expression of E6 in CasKi cells as well as their
ability to produce tumors in nude mice-we selected CasKi cells and
E6 protein for further in vitro and in vivo experiments.
Selection of a cell line-antigen combination to act as
an experimental Hepatitis B-associated
hepatocellular carcinoma (HCC) model
We evaluated two Hepatitis B-associated viral proteins as potential
targets for RIT-HBx and PreS2. HBx is suspected to have a role in
hepatocarcinogenesis and, unlike other potential choices, HBx has
no homology to host proteins. Further, the gene that codes for
HBx is retained even when the HBV genome becomes integrated
in HCC, whereas other HBV genes may be lost [21,22]. PreS2 is
also suspected to have a role in hepatocarcinogenesis (i.e., through
transactivation of cellular genes important in growth control) [22].
HBx protein was consistently detected by Western blot of HCC
cell line Hep 3B2.1-7 using 4H9 mAb, and its expression was
independent of pre-treatment with MG132 proteasome inhibitor
(Fig. 1f), whereas preS2 was not detected (results not shown).
Therefore, we selected the Hep 3B2.1-7 cell line and HBx protein
combination for further experiments.
Binding of antibodies to viral antigens in non-viable
cells
To find out if antibodies to viral proteins which were identified as
targets for RIT will be able to bind to viral proteins in non-viable
tumor cells, we performed immunofluorescence of fixed and
Figure 2. Detection of viral antigens in tumor cells and in tumors: a, b) immunofluorescence of fixed and permeabilized tumor cells. Left panels
show light microscopy images of the cells. Heavily damaged cells are marked with arrows. Right panels show immunofluorescent images of the same
slides treated with viral protein-specific mAbs followed by FTIC-conjugated polyclonal antibody to mouse IgGs: a–CasKi cells and E6-specific C1P5
mAb, b-Hep 3B2.1-7 cells and HBx-specific 4H9 mAb; c) immunohistochemistry of CasKi tumors. Left panel shows binding of E6-specific mAb C1P5.
Right panel shows absence of binding of control mAb 18B7; d) western blot of Hep 3B2.1-7 tumor with HBx-specific mAb 4H9.
doi:10.1371/journal.pone.0001114.g002
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E6 and 4H9 to HBx proteins, respectively, followed by FITC-
conjugated polyclonal antibody to mouse IgG. While the binding
of C1P5 mAb to the cells which were almost intact was weak, the
heavily damaged cells with penetrable membranes showed bright
fluorescence pointing to binding of C1P5 to E6 (Fig. 2a). The
fixation and permeabilization also made possible for mAb 4H9 to
bind to HBx protein (Fig. 2b). No binding of control IgG1 mAb to
fixed and permeabilized CasKi or Hep 3B2. 1-7 cells was observed
(results not shown).
Expression of viral proteins in the tumors
To confirm that CasKi and Hep 3B2.1-7 cells continued to
express E6 and HBx viral antigens, respectively, in the tumors
induced in nude mice, we performed immunohistochemistry
and immunoblot for E6 and HBx, respectively. Western blot
was chosen for Hep 3B2.1-7-induced tumors based on the
literature reporting difficulties in reliably detecting HBx protein
in organs by immunohistochemistry [23]. There was intense
staining of E6 with specific mAb C1P5 in CasKi tumors (Fig. 2c,
left panel) with no staining observed with control IgG1 mAb
(Fig. 2c, right panel). Western blot of Hep 3B2.1-7-induced
tumors revealed the presence of HBx protein (Fig. 2d). Thus,
the presence of the target viral proteins in CC and HCC
experimental tumors provided the possibility of targeting these
antigens in vivo with radiolabeled mAbs for scintigraphic
imaging and therapy.
Biodistribution of radiolabeled mAbs to viral
proteins in CasKi and Hep 3B2.1-7-tumor bearing
nude mice
We performed imaging and biodistribution experiments with
188Re-radiolabeled C1P5 and 4H9 mAbs in CasKi and Hep
3B2.1-7-tumor bearing nude mice, respectively, to ascertain the
localization of mAbs to the tumors. At 24 hr post-injection the
CasKi tumor was visible on the scintigraphic image of a mouse
injected with
188Re-C1P5 mAb (Fig. 3a) as opposed to the image
of a mouse injected with irrelevant
188Re-18B7 mAb (Fig. 3b). We
also calculated the tumor to muscle ratio from the 48 hr
biodistribution results which was 10:1 for
188Re-C1P5 versus 3:1
for
188Re-18B7. The overall uptake of
188Re-C1P5 mAb in the
tumors at 48 hr post-injection was 2.0(60.3)% of the injected dose
per gram tumor. Other organs like liver, spleen and blood showed
the levels of uptake characteristic of IgG1 mAbs. For Hep 3B2.1-7
we utilized another approach to prove the specificity of mAb
uptake in the tumor by using a model when a mouse carries two
different tumors–one the tumor of interest and another–irrelevant
control tumor. Nude mice carried A2058 human metastatic
melanoma tumor on the right flank and Hep 3B2.1-7 on the left
(Fig. 3c). The mice were injected with
188Re-4H9 mAb and
imaged scintigraphically at 24 hr post-injection. The antibody
localized to the Hep 3B2.1-7 tumor as opposed to the irrelevant
control melanoma tumor (Fig. 3d). The ability of radiolabeled
mAbs to viral antigens to localize to these tumors in mice justified
an assessment of RIT in these in vivo cancer models.
Figure 3. Scintigraphic images of tumor-bearing mice 24 hours post-injection with: a) CasKi tumor, E6-specific mAb
188Re-C1P5 mAb; b) CasKi
tumor, control
188Re-18B7 mAb; c) Hep 3B2.1-7 and A2058 human metastatic melanoma tumors, HBx-specific
188Re-4H9 mAb.
doi:10.1371/journal.pone.0001114.g003
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mice
To evaluate the therapeutic effect of
188Re-C1P5 mAb in CasKi
tumor-bearing mice, the animals were injected with either 350 mCi
188Re-C1P5 mAb, or matching amounts (30 mg per mouse) of
unlabeled (‘‘cold’’) C1P5 mAb or left untreated. Fig. 4a shows the
change intumor volumeinthe treated and control groups.RIT with
350 mCi
188Re-C1P5 mAb completely arrested tumor growth and
resulted in its volume reduction (Fig. 4a and b), while untreated
tumors grew aggressively (Fig. 4a and c) and untreated control mice
had to be sacrificed on Day 20 post-treatment (P,,0.01).
Interestingly, administration of ‘‘cold’’ C1P5 mAb also resulted in
significant retardation of the tumor growth, which can be due to the
induction of inflammation and complement cascades by the mAb.
For RIT of Hep 3B2.1-7 tumors in nude mice we initially
employed the same experimental design as for CasKi tumors by
using 350 mCi
188Re-4H9 mAb, ‘‘cold’’ mAb-treated controls and
untreated groups. Administration of 350 mCi
188Re-4H9 mAb
resulted in slower tumor growth but did not arrest it like in case of
CasKi tumors. ‘‘Cold’’ 4H9 mAb did not have an effect on the
tumor growth. To find the most efficient dose of radiolabeled mAb
for retarding the growth of very aggressive Hep 3B2.1-7 a dose
response experiment was done. The therapeutic effect of
188Re-
4H9 mAb began to manifest itself at a dose of 280 mCi and the
effect increased with every subsequent increase in the dose (Fig. 5a)
(P,0.02). At the completion of the experiment the tumors from
the control untreated mice and mice in the highest 600 mCi group
were analyzed histologically. The control tumor consisted of
moderately differentiated hepatoid cells with scattered small foci of
necrosis, fibrin thrombosis, and hemorrhage. Neoplastic cells had
ample eosinophilic to finely vacuolated cytoplasm and medium-
sized nuclei to very large and anaplastic nuclei containing multiple
large eosinophilic nucleoli with multinucleated cells occasionally
evident. The mitotic index was high and there were scattered
apoptotic cells (Fig. 5b). In contrast, the RIT-treated tumors had
significantly more necrosis and hemorrhage than seen in the
controls. The morphologic appearance of the tumor cells often
had a more vacuolated cytoplasm suggesting degeneration (Fig. 5c).
DISCUSSION
We performed proof-of-principle in vitro and in vivo experiments
to establish the feasibility of targeting viral antigens in tumors of
viral etiology with radiolabeled antibodies for therapy. To this end,
we studied experimental cervical carcinoma (CC) and hepatocel-
lular carcinoma (HCC) models, since these cancers are etiologi-
cally related to HPV and HBV/HCV, respectively, and have
major public health implications world-wide.
The first challenge was the choice of target viral antigens in CC
and HCC. In HPV-associated CC we identified E6 and E7
oncoproteins as potential targets for RIT, because they are
thought to be expressed in all cervical cancer cells; whereas, other
viral genes may be lost during the multi-stage process of
tumorigenesis. Similarly, in HCC, HBx expression is thought to
be maintained. There is, however, an important concern in
targeting these three proteins with radiolabeled mAbs–their
subcellular location. Both E6 and E7 are located within the
nucleus, and HBx is found in the nucleus and occasionally in the
cytoplasm. As a consequence, the radiolabeled mAbs to these
proteins can bind only to their respective antigens when they are
released from the dead cells or when tumor cells are permeabi-
lized. To conduct these experiments, we chose the CasKi cell line
as a CC model, since we found it expressed E6 and E7 at high
levels in vitro and the tumors grew aggressively in nude mice after
the latent period. The Hep 3B2.1-7 cell line was chosen as a HCC
model, after we observed that it expressed HBx at high levels and
displayed fast tumor growth in mice.
The immunofluorescence of the tumor cells and immunohisto-
chemistry and Western blot of the tumors revealed ample amounts
of E6 and HBx antigenic targets in CasKi- and Hep 3B2.1-7-
induced tumors, respectively (Fig. 2). The presence of accessible
antigen for the radiolabeled mAbs is probably a result of protein
release from tumor cells undergoing rapid turnover. Consequently,
the radiolabeled antibodies accumulated in the tumor tissue such
that they could be imaged scintigraphically (Fig. 3). One of the
advantages of targeting viral antigens in the tumors that they are
only found in malignant cells. In contrast, Chen and colleagues
observed no differences in the tumor uptake for both specific and
non-specific radiolabeled antibodies in their biodistribution
experiments when they targeted intranuclear histones [24].
The ability of radiolabeled mAbs against viral proteins to deliver
cytotoxic radionuclide 188-Rhenium to the tumor cells facilitated
the successful outcomes of RIT with these mAbs in tumor-bearing
mice. The administration of 350 mCi dose of E6-binding
188Re-
C1P5 mAb to CasKi tumor-bearing mice completely stopped
tumor growth and even resulted in its regression (Fig. 4). It is also
likely that there was some added therapeutic benefit from the
antibody itself as unlabeled antibodies can mediate inflammatory
reactions and activate compliment. In the future, it will be
worthwhile to investigate whether increased cellular levels of E6
and E7 oncoproteins could be obtained with pretreatment use of
MG132 in vivo, and whether this results in a therapeutic benefit.
The dose response experiments in mice bearing Hep 3B2.1-7 HCC-
tumors clearly demonstrated a dose dependence for the therapeutic
effect (Fig. 5). The fact that higher doses of radiolabeled mAb were
needed to produce a therapeutic effect in HCC than in cervical
tumor might reflect the aggressiveness of Hep 3B2.1-7 and the
known radioresistance of liver tumors in comparison to the relatively
radiosensitive cervical carcinomas [25]. It is also noteworthy that
therapeutic gains in both experimental tumors were achieved with
doses of radioactivity that are well below the maximum tolerated
doseofapproximately800 mCifor
188Re-labeledIgG1sinmice[26],
and as such the doses used were not expected to produce any short-
or long-term toxicities.
It is important to emphasize that when treating viral-associated
cancers by targeting viral antigen not every cell in the tumor needs
to express viral antigens for a therapeutic effect. Long range
emitters such as
188Re (emission range in tissue 10 mm) emit
radiation in a 360u sphere and consequently can kill cells in the
vicinity of the antigen location. Furthermore, a high concentration
of the targeted viral antigen is probably not required for the
delivery of a therapeutic dose to the tumor, according to our
recent model of RIT for melanoma (targeted against melanin
which is also an intracellular antigen). This model showed that the
radiation dose delivered to the tumor is largely independent of
melanin (antigen) concentration [27].
This approach also holds the promise to prevent viral-associated
cancers in chronically infected individuals-for example, persistence
of HPV infection in HIV-infected individuals puts them at
significant risk of developing HPV-associated cancers. While there
is immunotherapy for HBV and HCV, many patients do not
achieve viral clearance and the treatment is associated with
substantial morbidity. There is also no vaccine for HCV, and
many millions of people worldwide are infected with HBV despite
the availability of an effective vaccine. Cells persistently infected
with HPV, HBV, HCV or other viruses could potentially be
eliminated with RIT targeted to viral antigens before they
transform into malignant phenotype.
Viral Cancer Targets
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188Re-C1P5 mAb; c)
control mouse (both mice shown on Day 20 post-treatment).
doi:10.1371/journal.pone.0001114.g004
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assess a novel strategy to treat virus associated tumors using
radiolabeled mAbs targeted against viral proteins. This strategy is
fundamentally different from prior uses of RIT in oncology that
target tumor-associated human antigens thus resulting in signifi-
cant uptake of radioactive antibody in normal tissues, leading to
toxicity. The results of our study suggest that by targeting instead
viral and not self-proteins it may be possible for radiolabeled mAbs
to concentrate more specifically within tumor tissue, resulting in
greater efficacy and less toxicity. This strategy also raises an
exciting additional possibility to prevent virus-associated cancers in
chronically infected patients by eliminating cells infected with
oncogenic viruses before they transform into cancer.
METHODS
Antibodies
Mouse mAbs from Abcam C1P5 to HPV16 E6+HPV18 E6 and
TVG 701Y to HPV16 E7 were used in CC experiments. Mouse
mAb 4H9 to HBV HBx (Aviva, Cat# AVAMM2005) and mouse
mAb S26 to HBV protein Hbs (Gene Tex Inc. Cat# GTX18797)
which cross-reacts with HBsAg preS2 antigen were used in HCC
experiments. Murine 18B7 mAb (IgG1) to C. neoformans [28] was
used as an irrelevant control for all specific antibodies. Rabbit
polyclonal antibody conjugated with alkaline phosphatase to
mouse IgG H&L was purchased from Abcam and used as
secondary antibody in Western blot.
Figure 5. Radioimmunotherapy of Hep 3B2.1-7 tumors in nude mice: a) changes in tumor volume; b) control untreated mouse; c) mouse treated
with 600 mCi
188Re-4H9 mAb. Both mice shown on Day 18 post-treatment. In b and c lower panels show H&E stained tumors at the completion of the
experiment.
doi:10.1371/journal.pone.0001114.g005
Viral Cancer Targets
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Three human cervical carcinoma cell lines: Hela S3, SiHa and
CasKi were purchased from ATCC (Manassas, VA). Cells were
grown routinely in DMEM/HAM F-12K (Sigma, 1:1) containing
10% FBS (Sigma) and 1% Penicillin-streptomycin solution (Sigma,
penicillin 10,000 U and streptomycin 10 mg/ml) at 37uCi n5 %
CO2 incubator. The cell line Hep 3B2.1-7 (Homo sapiens hepatato-
cellular carcinoma) was purchased from ATCC. It contains an
integrated hepatitis B virus genome and was derived from the
hepatocellular carcinoma tissue of 8-year old black boy. Cells were
grown routinely in Eagle’s Minimum Essential Medium (EMEM)
(ATCC) containing 10% FBS (Sigma) at 37uCi n5 %C O 2
incubator. Cell layers in 75 ml flask was dispersed by adding 2 ml
16Trypsin-EDTA solution (Sigma, 0.25% (w/v) trypsin20.53 mM
EDTA) at room temperature for 15 minutes. A2058 cellline derived
from a lymph node metastasis from patient with malignant
melanoma was obtained from ATCC. The cells were maintained
as monolayers in Dulbecco’s Modified Eagle’s Medium with 4 mM
L-Glutamine, 4.5 g/L glucose, 1.5 g/L sodium bicarbonate,
supplemented with 10% fetal bovine serum and 5% penicillin-
streptomycin solution at 37uC and 5% CO2,a n dh a r v e s t e db yu s i n g
0.25% (w/v) Trypsin-EDTA solution. Routine maintenance of all
cell lines was performed according to the ATCC protocols.
Western blots
Cell pellets were suspended in the lysis buffer (4% SDS, 20%
glycerol, 0.5 M TrisHCl (pH 6.8), 0.002% bromophenol blue and
10% b2mercaptoethanol). Protein samples were boiled in water for
15 min before running SDS-PAGE. Twenty five-thirty mlp r o t e i n
solution was loaded into each well of 12% precast SDS-PAGE gel
(Bio-Rad). SDS-PAGE was used to monitor the relative protein
amounts in the samples. Twelve percent SDS-PAGE gel was used to
separate proteins, and electrophoresis was performed using Mini-
ProteanH 3 Cell system (Bio-Rad). After electrophoresis, the gel was
transferred into the PVDF transfer buffer (25 mM Tris, 190 mM
glycine and 2.5% (v/v) methanol) for 5 min. Then, proteins were
transferred from the gel to the Immun-Blot
TM PVDF membrane
(Bio-Rad) on Semi-dry Electrophoretic Transfer Cell (Bio-Rad) at
15 V for 17 min. The membrane was soaked in the blocking buffer
(25 mM TrisHCl (pH7.6), 1 mM EDTA and 150 mM NaCl) for
5 min, and then transferred into the blocking solution (5% non-fat
dry milk in the blocking buffer), shaking gently for an hour. The
membrane was incubated in TBST solution (0.1% Tween-20,
25 mM TrisHCl (pH7.6) and 500 mM NaCl) containing 1:3000
diluted primary antibody at room temperature for 1 hour with
gentle shaking. Then, the membrane was washed with TBST three
times (10 min per wash). The membrane was hybridized by the
secondary antibody conjugated with alkaline phosphatase (Rabbit
polyclonal to mouse IgG H&L (alkaline phosphatase)) in TBST with
a 1:100,000 dilution. After three washes with TBST, the membrane
was incubated in CDP-Star
TM chemiluminescent substrate solution
(Sigma) for 5 min,and then exposed to CL-XPosure
TMfilm(Pierce).
The film was developed as per manufacturer’s instructions.
MG132 treatment of cells
MG132 (Z-LLL-CHO, MW=457.6) purchased from CALBIO-
CHEM is a potent, reversible and cell-permeable proteasome
inhibitor (Ki=4 nM). MG132 was first dissolved in a drop of 100%
ethanol followed by DMEM/HAM F-12K medium without
addition of FBS, and the stock solution was stored at 4uC. Cell
culture was harvested and transferred into 6 sterile test tubes. Each
tube contained 0.5–1 ml cell culture (cell concentration was
,10
6 cells/ml), and cells were allowed to grow at 37uCi n5 %
CO2 incubator overnight. Then, MG132 solution was added to the
tubes for the final concentrations of 0, 1,2, 5, 10 or 25 mg/ml(0, 2.1,
4.2,10.5,21or52 mM,respectively).Thecellswereincubatedunder
the same conditions for another 3 or 6 hours. Finally, cells were
harvested by centrifugation and clarified by washing with PBS.
Radioisotope and radiolabeling of the antibodies
The beta-emitter
188Re with a half life of 16.9 hours was eluted in
the form of sodium perrhenate Na
188ReO4 from an
188W/
188Re
generator (Oak Ridge National Laboratory, Oak Ridge, TN).
Antibodies were labeled with
188Re directly through binding of
reduced
188Re to the generated2SH group on the antibodies as
previously described [11].
Immunofluorescent detection of viral antigens in
tumor cells
The tumor cells were grown in the slide chambers at 37uC for
12 hrs. The medium was removed and the cells were washed with
PBS three times. Throughout the procedure, the cells were washed
3 times with PBS after each treatment. They were fixed with 4%
paraformaldehyde at room temperature for 20 min followed by
permeabilization with 0.3% Triton-X100 in PBS at room
temperature for 10 min. Fixed and permeabilized cells were
blocked with 5% BSA plus 0.1% Triton X-100 in PBS at room
temperature for 30 min. Viral antigens-specific mAbs were diluted
1:200 with the above BSA and Triton X-100 solution and
incubated with the cells at room temperature for 60 min. FTIC-
conjugated rabbit polyclonal antibody to mouse IgG in 1:300
dilution was added to the cells for 60 min incubation at room
temperature in the dark. The slides were viewed with an Olympus
AX70 microscope (Melville, NY) equipped with a FITC filter.
Tumor models
All animal studies were carried out in accordance with the guidelines
of the Institute for Animal Studies at the Albert Einstein College of
Medicine. Human cervical carcinoma CasKi and human hepato-
cellular carcinoma Hep 3B2.1-7 cell lines were chosen as the tumor
models based on its expression of E6 and HBx, respectively, and
their tumorigenecity in nude mice. Six-week-old female Nu/Nu
CD1nudemicepurchasedfromCharlesRiverwereinjectedintothe
right flank with 10
7 CaSki or Hep 3B2.1-7 cells in 0.1 ml DMEM
medium containing 10% fetal calf serum. CasKi tumors began to
appear around 60 days after injection, Hep 3B2.1-7 tumors-10 days
post cell injection. For biodistribution of HBx-specific mAb, nude
mice were inoculated with 10
7 A2058 human metastatic melanoma
cells and 10
7 Hep 3B2.1-7 cells into the right and left flanks,
respectively. Biodistribution and therapy experiments were initiated
when the tumors reached 0.3–0.7 cm in diameter.
Immunohistochemical detection of HPV E6 protein
in CasKi tumors
The tumors taken from CasKi tumor-bearing mice were fixed in
10% buffered formalin overnight, followed by placing in 70%
ethanol. The paraffin-embedded tumor tissues were cut into 5 mm
slides. The sections were deparaffinized in xylene and dehydrated
in graded ethanol continuously, and pre-treated with citrate buffer
(pH 6.0) at 100uC for 20 min to retrieve the antigen. The sections
were treated with 3% hydrogen peroxide in methanol in order to
block the endogenous peroxidase activity. IHC staining of the
tumor tissue sections was then performed using HistostainH-Plus
Kits ZymedH 2
nd Generation LAB-SA Detection System (Invitro-
gen) according to the manufacturer’s instruction. Mouse mAb
Viral Cancer Targets
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tumor tissues, and the negative control was incubated with 18B7
mAb instead of primary antibody under the same conditions.
Other reagents used in IHC were supplied with the kit.
Western blot detection of HBx antigen in Hep
3B2.1-7 tumors
The Hep 3B2.1-7 tumors were homogenized on ice and western
blot was performed as described above.
Biodistribution and scintigraphic imaging with
188Re-labeled mAbs
For biodistribution and scintigraphic imaging in CasKi or Hep
3B2.1-7 tumor-bearing mice, mice were divided into groups of
three and injected IP with either 100 mCi of specific mAbs
188Re-
C1P5 or
188Re-4H9 or with control mAb
188Re-18B7. Twenty-
four hours post-injection mice were anesthetized with Isoflurane
and scintigraphically imaged for 2 min on a Siemens gamma
camera equipped with ICON image processing software. Forty
eight hours post-injection mice were sacrificed and the tumors and
muscle were removed, blotted from blood, weighted, counted in
a gamma counter and percentage of injected dose per gram tissue
and tumor to muscle ratios were calculated.
Therapy of CaSki and Hep 3B2.1-7 tumors in nude
mice with
188Re-labeled mAbs
For therapeutic studies mice with tumors of 0.3–0.7 cm in
diameter were randomized into the groups of six. For CasKi
tumor-bearing mice, group # 1 was treated IP with 350 mCi
188Re-C1P5 mAb, group # 2–with matching amount (30 mg)
‘‘cold’’ C1P5 mAb, and group # 3 was left untreated. For RIT of
Hep 3B2.1-7 tumor-bearing mice, group # 1 was given IP
240 mCi
188Re-4H9 mAb, group # 2–280 mCi, # 3–350 mCi, #
4–500 mCi, # 5–600 mCi of
188Re-4H9 mAb, # 6–30 mg ‘‘cold’’
4H9 mAb and group # 7 was left untreated. Mice were observed
for their well–being and tumor growth. The size of the tumor was
measured every 3 days with calipers in three dimensions and the
tumor volume was calculated as a product of three dimensions
divided by 2. For histological analysis the tumors were removed
from the mice at the completion of the experiments, fixed in
buffered formalin, parafinized, cut into 5 mm slices and stained
with hematoxylin and eosin (H&E).
Statistical analysis
Non-parametric Wilcoxon Rank Sum test was used to compare
organs uptake in biodistribution studies and tumor sizes in therapy
studies. The differences were considered statistically significant
when P values were,0.05.
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